Peer-reviewed veterinary case report
Blood tests for nasal disease diagnosis in dogs
By Rösch, Sarah et al.·Published in Frontiers in veterinary science·2025·Small Animal Department, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Diagnostic value of serum survivin, Ki-67 and thymidine kinase in dogs with nasal cavity disease.
- Species:
- dog
Plain-English summary
A group of dogs with nasal discharge underwent testing to check for nasal cavity disease, which can include serious issues like tumors. Researchers found that certain blood markers, specifically survivin and the survivin-lymphocyte ratio, were higher in dogs with malignant nasal tumors compared to healthy dogs. While these markers aren't definitive for diagnosing nasal disease, they could help in monitoring the disease or detecting smaller tumors earlier. This means that if your dog has nasal problems, discussing these blood tests with your veterinarian might be beneficial for early detection and treatment options.
People also search for: dog nasal discharge treatment · nasal tumor in dogs symptoms · blood tests for dog nasal cancer
Abstract
BACKGROUND: The most common nasal cavity disease (ND) in dogs is the malignant nasal cavity tumor. Prognosis and survival after radiation therapy are reported to correlate with tumor size, and therefore indirectly with the time to diagnosis. Diagnosis of a nasal tumor requires imaging procedures under anesthesia. Thus, diagnostic serum markers are urgently needed for early detection and for therapeutic monitoring. MATERIALS AND METHODS: This prospective, blinded study included dogs with nasal discharge that completed a comprehensive diagnostic workup for ND. Dogs were evaluated by blood testing and whole-body CT and those with concomitant diseases or with steroid pre-treatment were excluded. Serum survivin, Ki-67, and thymidine kinase 1 (TK1) concentrations were determined, and the survivin-lymphocyte ratio (SLR) calculated. Results were compared between groups of dogs with different NDs and to ten healthy controls. RESULTS: A total of 55 dogs were included, consisting of 25 with malignant ND (12 sarcomas, 13 carcinomas) and 30 with benign ND (7 benign tumors, 13 dogs with idiopathic rhinitis (IR), 10 others including dogs with dental diseases and sinonasal aspergillosis). Survivin and SLR were significantly increased in dogs with malignant ND and in subgroup comparison in sarcomas compared to controls. In addition, the SLR was significantly increased in carcinomas and IR compared to controls. In dogs with IR, no differences were observed in survivin concentrations or SLR based on microbiological or histopathological findings. Survivin concentrations or SLR in dogs with nasal tumors were not significantly different between T-categories. No significant differences were detected in TK1 concentrations among the groups, nor in Ki-67, except for significantly lower Ki-67 concentrations in benign tumors compared to carcinomas and the group others including, e.g., dental diseases. CONCLUSION: Although not diagnostic for ND, increased survivin serum concentrations or SLR can be detected in dogs with malignant nasal tumors and IR. In malignant nasal tumors, survivin and SLR did not correlate with tumor size and therefore may be useful in the detection of even small nasal tumors. Therefore, in dogs with nasal tumors and IR, survivin and SLR could serve as a target for disease monitoring or as therapeutic target.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/40260215/